tailieunhanh - Báo cáo y học: " The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:" The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. | Taniguchi et al. Respiratory Research 2011 12 93 http content 12 1 93 RESPIRATORY RESEARCH RESEARCH Open Access The clinical significance of 5 change in vital capacity in patients with idiopathic pulmonary fibrosis extended analysis of the pirfenidone trial I_I I I 11 1 I s I I iT-h I 1 f A r I I I I r IX z I z pg f l I s r s A i z c Pk 1 2 A A 7I I m s2 I s I r p I AAz-i I I K 4 r p I z I s I I p 15 HiroyuKi lanigucni Yasuniro Kondon Masaniio tbina Araia Azuma laKasni Ogura Yosnio lagucni A I KI s I Cl Iz t s6 I_I I I I T- I 1 p S 1 p I 2 IX I r p I rrs l I s I s 8 A r I I p I l z c S9 II I p 11 Cl I z t I m s 19 c p II IXI I Iz 1 3 MoriiaKa Suga HiroKi laKanasni Koichiro NaKaia AisuniKo Saio YUKiniKo Sugiyama snoji Kuaon Toshihiro NuKiwa2 and for Pirfenidone Clinical Study Group in Japan Abstract Background Our pnase III clinical trial of pirfenidone for paiienis wiin idiopainic pulmonary fibrosis IPF revealed ine efficacy in reducing ine decline of viial capacity VC and increasing ine progression-free survival PFS time by pirfenidone. Recenily marginal decline in forced VC FVC nas been reported io be associated wiin poor ouicome in IPF. We sougni io evaluate ine efficacy of pirfenidone from ine aspecis of 5 cnange in VC. Methods Improvemeni ratings based on 5 cnange in absolute VC . improved VC 5 increase siable VC 5 cnange and worsened VC 5 decrease ai monin 3 6 9 and 12 were compared beiween nign-dose pirfenidone 1800 mg day n 108 and placebo n 104 groups and nign-dose and low-dose 1200 mg day n 55 pirfenidone n 163 and placebo groups. PFS iimes wiin defining ine disease progression as deain or a 5 decline in VC were also compared beiween nign-dose pirfenidone and placebo groups and low-dose pirfenidone and placebo groups. Furthermore considering worsened and non-worsened improved and siable of ine ratings ai monins 3 and 12 as posiiive and negaiive respeciively and ine posiiive and negaiive prediciive values of ine raiings were .